NCT04278768 2026-03-19
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Curis, Inc.
Phase 1/2 Suspended
Clinical Trials
135 trialsNCT06846671 2026-03-19
CaDAnCe-302
BeOne Medicines
Phase 3 Recruiting
NCT06852222 2026-03-19
cAMeLot-2
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06943872 2026-03-19
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines
Phase 3 Recruiting
NCT04256317 2026-03-18
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology, Inc.
Phase 2/3 Recruiting
NCT05275439 2026-03-18
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Shattuck Labs, Inc.
Phase 1 Terminated
NCT07277231 2026-03-18
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 3 Recruiting
NCT03547115 2026-03-17
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
MEI Pharma, Inc.
Phase 1 Terminated
NCT04227847 2026-03-16
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
Seagen Inc.
Phase 1 Recruiting
NCT04588922 2026-03-16
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Phase 1/2 Recruiting
NCT05735184 2026-03-13
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc.
Phase 1 Recruiting
NCT05963074 2026-03-13
TAILOR
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT03462719 2026-03-12
GLOW
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05453903 2026-03-12
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT03336333 2026-03-09
SEQUOIA
BeOne Medicines
Phase 3 Active not recruiting
NCT06456463 2026-03-09
TRILLIUM
Stemline Therapeutics, Inc.
Phase 2 Recruiting
NCT03844048 2026-03-06
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie
Phase 3 Active not recruiting
NCT07255872 2026-03-05
A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3 Not yet recruiting
NCT03331198 2026-03-04
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Juno Therapeutics, a Subsidiary of Celgene
Phase 1/2 Recruiting
NCT04623541 2026-03-04
EPCOREâ„¢ CLL-1
Genmab
Phase 1/2 Active not recruiting
NCT05520567 2026-03-04
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
Astellas Pharma Inc
Phase 1/2 Active not recruiting
NCT06073821 2026-03-04
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
BeOne Medicines
Phase 3 Active not recruiting
NCT05091424 2026-03-03
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 1 Recruiting
NCT06524375 2026-02-25
BRAVE
Genentech, Inc.
Phase 2 Active not recruiting
NCT05428969 2026-02-20
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2 Active not recruiting
NCT05057494 2026-02-18
MAJIC
AstraZeneca
Phase 3 Active not recruiting
NCT04895436 2026-02-09
ReVenG
AbbVie
Phase 2 Recruiting
NCT06372717 2026-02-04
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
Apollo Therapeutics Ltd
Phase 1 Recruiting
NCT03123029 2026-01-30
Expanded Access to Venetoclax
AbbVie
Available
NCT04965493 2026-01-29
BRUIN CLL-322
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03740529 2026-01-27
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Eli Lilly and Company
Phase 1/2 Completed
NCT03926624 2026-01-22
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Delta-Fly Pharma, Inc.
Phase 3 Terminated
NCT05001828 2026-01-21
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia
Polaris Group
Phase 1 Active not recruiting
NCT07024706 2026-01-21
MAVRiC
AstraZeneca
Phase 2 Not yet recruiting
NCT04150029 2026-01-13
STIMULUS-AML1
Novartis
Phase 2 Terminated
NCT07044687 2026-01-12
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
AbbVie
Phase 4 Recruiting
NCT05201066 2026-01-07
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Novartis
Phase 2 Active not recruiting
NCT02966756 2025-12-24
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
AbbVie
Phase 2 Recruiting
NCT07154264 2025-12-24
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Dizal Pharmaceuticals
Phase 2 Recruiting
NCT02296918 2025-12-19
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
Acerta Pharma BV
Phase 1 Completed
NCT04068597 2025-12-18
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
Phase 1/2 Recruiting
NCT04657081 2025-12-08
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
Taiho Oncology, Inc.
Phase 1/2 Active not recruiting
NCT04937166 2025-11-10
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
Kahr Medical
Phase 1 Terminated
NCT02242942 2025-11-06
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 3 Completed
NCT06428019 2025-11-05
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
AbbVie
Phase 3 Recruiting
NCT06419634 2025-10-30
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Bristol-Myers Squibb
Phase 1 Recruiting
NCT04266795 2025-10-21
PEVENAZA
Takeda
Phase 2 Completed
NCT05105841 2025-10-15
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
AbbVie
Phase 2 Completed
NCT04581512 2025-10-14
Study to Evaluate the Safety and Tolerability of EP0042
Ellipses Pharma
Phase 1/2 Recruiting
NCT06563804 2025-10-14
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Servier
Phase 1/2 Terminated